Monitoring Treatment Response to Tafamidis by Serial Native T1 and Extracellular Volume in Transthyretin Amyloid Cardiomyopathy
Yasuhiro Shintani(National Cerebral and Cardiovascular Center), Chisato Izumi(National Cerebral and Cardiovascular Center), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Yasuhiro Hamatani(National Cerebral and Cardiovascular Center), Yoshiki Sekijima(Shinshu University), Hatsue Ishibashi‐Ueda(United Cerebral Palsy), Atsushi Okada(National Cerebral and Cardiovascular Center), Makoto Amaki(National Cerebral and Cardiovascular Center), Tsuneaki Yoshinaga(Shinshu University), Keiko Ohta‐Ogo(National Cerebral and Cardiovascular Center), Yoshiaki Morita(Osaka City University), Chihiro Shimazaki(Kyoto Prefectural University of Medicine), Masahide Yazaki, Masashi Amano(National Cerebral and Cardiovascular Center), Hiroyuki Takahama(Tohoku University), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Satoshi Yasuda(Tohoku University)
Cited by 18
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456